Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.75
Bid: 10.50
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 0.50 (4.762%)
Open: 10.75
High: 10.75
Low: 10.75
Prev. Close: 10.75
ABDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AppDx® granted further patent

7 Mar 2023 07:00

RNS Number : 0713S
Abingdon Health PLC
07 March 2023
 

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

AppDx® lateral flow smartphone reader granted further patent

 

York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its AppDx® lateral flow smartphone reader.

 

AppDx® is a software development kit (SDK) for reading colorimetric lateral-flow tests (LFT) organized for Android™ and iOS® smartphone operating systems. AppDx® enables lateral-flow test readout from your pocket, enabled by a smartphone camera, that can be used by any user app. It consists of a software Application Programming Interface (API) accessed as a library which contains algorithms for image processing and deep learning in order to read a lateral-flow test using a smartphone. The algorithms need to be customized and tuned for each test. The Abingdon Health AppDx® algorithm reads the lateral flow device qualitatively (e.g. positive/negative) and semi-quantitively (e.g. negative/high/medium/low). A key point of differentiation is that the algorithm may be located on the smartphone, therefore not requiring a Wifi connection or 4G connection. It can also be provided as a web server-based solution.

 

The granted patent (GB 2601978) relates to the use of a plurality of captured images to provide a more refined algorithm which allows variations in imaging conditions to be averaged out and/or outliers removed. This allows the algorithm to counteract typically seen issues with measuring lateral flow devices such as specks of dust, reflections other artefacts and importantly different lighting conditions. These are important factors when considering the use of lateral flow tests in a range of different environments such as the home, doctor's office, veterinary office, farm or field. This innovation therefore is of critical importance in enabling the application of AppDx® commercially across a range of applications. 

 

This is the third patent granted to Abingdon Health in relation to AppDx®, including the granting of patent GB 2583419 which covers the use of neural-network based detection of lateral-flow tests, extracting the region-of-interest, and processing the data to calculate the values of the assay lines. This covers the two-stage pipeline where the assay area is extracted from the picture and image processing algorithms measure the line values and positions.

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are pleased to announce the granting of a further patent for our AppDx® smartphone lateral flow reader. Given the expected rapid growth in the lateral flow self-test market we believe the use of smartphone apps, such as AppDx®, will be critical in allowing widespread adoption of lateral flow rapid-testing.

 

"This patent grant underlines Abingdon's focus on innovation to support its customers and we now look forward to initiating commercial discussions to bring this product to market."

 

 

Enquiries

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross, Chief Financial Officer

 

 

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

+44 (0)7407 804 654

 

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPUAGWUPWGBQ
Date   Source Headline
31st May 20247:00 amRNSTotal Voting Rights – 31 May 2024
15th May 20247:00 amRNSLaunch of the Saliva Pregnancy self-test in Boots
8th May 20247:00 amRNSChange of Nominated Adviser and Sole Broker
7th May 20247:00 amRNSAcquisition of IVDeology Holdings Limited
25th Mar 20247:00 amRNSDesign freeze completion & strategic partnership
20th Mar 20247:00 amRNSLaunch of OEM self-tests in Boots
15th Mar 20241:00 pmRNSCEO Interview
14th Mar 20247:00 amRNSInterim Results
11th Mar 20248:53 amRNSNotice of Results
11th Jan 20247:01 amRNSUpdate to Shareholder Concert Parties
11th Jan 20247:00 amRNSTrading Update
15th Dec 202310:15 amRNSResult of AGM
15th Dec 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSNotice of Annual General Meeting
25th Oct 20237:00 amRNSDirector/PDMR Shareholding
24th Oct 20237:01 amRNSAward of Options under LTIP
24th Oct 20237:00 amRNSAppointment of Interim Finance Director
18th Oct 20237:00 amRNSDirectorate Change
17th Oct 20237:00 amRNSFinal Results
11th Oct 20237:00 amRNSNotice of Results
7th Sep 20237:00 amRNSPartnership with Morrama
30th Aug 20237:00 amRNSAgreed changes to Concert Party
15th Aug 20237:00 amRNSSalistick™ to be launched in Tesco
6th Jul 20237:00 amRNSTrading Update
19th Jun 20237:00 amRNSLaunch of Salistick™ saliva pregnancy test
31st Mar 20237:00 amRNSInterim Results
24th Mar 202312:30 pmRNSNotice of Results
20th Mar 20237:00 amRNSSenzo & Abingdon enter into strategic partnership
7th Mar 20237:00 amRNSAppDx® granted further patent
1st Mar 20237:00 amRNSDirector Share Transfer to Trust
28th Feb 20239:05 amRNSSecond Price Monitoring Extn
28th Feb 20239:00 amRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTrading Update
19th Dec 202210:29 amRNSResult of AGM
19th Dec 20227:01 amRNSAward of Options under new LTIP Scheme
19th Dec 20227:00 amRNSAGM Statement
24th Nov 20229:05 amRNSSecond Price Monitoring Extn
24th Nov 20229:00 amRNSPrice Monitoring Extension
24th Nov 20227:00 amRNSPreliminary Results
23rd Nov 20227:00 amRNSNotice of AGM and Notice of Results
10th Oct 202211:06 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSFurther re. Outcome of Judicial Review
7th Oct 20225:16 pmRNSFurther re. Outcome of Judicial Review
7th Oct 20224:41 pmRNSSecond Price Monitoring Extn
7th Oct 20224:36 pmRNSPrice Monitoring Extension
7th Oct 20223:29 pmRNSOutcome of Judicial Review
7th Oct 20222:06 pmRNSSecond Price Monitoring Extn
7th Oct 20222:00 pmRNSPrice Monitoring Extension
7th Oct 202210:35 amRNSJudicial Review – judgement expected at 3pm

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.